NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weill Cornell Medical College in New York announced findings at the American Society of Hematology Annual Meeting of a phase III, double blind, placebo-controlled study randomising patients to have idelalisib or placebo added to their rituximab treatment. He discussed the clinical implications with AudioMedica.com of the extension of both progression-free and overall survival among patients receiving the new agent in comparison with placebo. Jennifer Brown MD PhD, Director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute in Boston added her comments and explained why she considered idelalisib is a good candidate for early approval.
You may also like...
Advanced, unresectable melanoma: survival rates at five years doubled with ipilimumab therapy 26 Oct, 2013 Prostate Genomics—Which Patients Will Die? 20 Apr, 2017 Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson” 12 Nov, 2018 Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer 8 Jun, 2018
- Previous story Osteoporosis: sclerostin inhibitor romosozumab increased bone mineral density
- Next story Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014